Biden’s Abortion Strategy Omits Regulatory Changes That Could Boost Mifepristone Access
Executive Summary
HHS report on protecting reproductive care shows administration is reluctant to take bold actions to counter Supreme Court’s Dobbs decision. Report does not suggest revising or eliminating mifepristone’s REMS or seeking preemption legal battles as some advocates have urged.
You may also be interested in...
Mifepristone REMS For Pharmacies Contains Some Unusual Provisions, Continues Debate Over Access
After FDA clears modified REMS, certified retail pharmacists are permitted to dispense the abortion medication. Some advocates argue program is unnecessary, while others want a broader federal effort to expand access. Walgreens intends to become a certified pharmacy.
Medical Organizations Push For Mifeprex Miscarriage Indication, REMS Elimination
The American College of Obstetricians and Gynecologists and 48 other groups request the FDA ask Danco Laboratories to file a supplemental NDA for an expanded indication and eliminate requirements for provider and pharmacist certification. For now, Danco is focused on updating the REMS as modified in December.
Mifepristone Access Swings In The Balance In Post-Roe World
The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.